2025-2034 End Stage Renal Disease (ESRD) Drug Market Evolution: Disruptions, Innovations, and Untapped Opportunities

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the End Stage Renal Disease (ESRD) Drug Market Through 2025?
The market size for drugs treating end stage renal disease (esrd) has seen robust growth in the recent past. A boost from $131.41 billion is expected in 2024 to reach $148.55 billion in 2025, marking a compound annual growth rate (CAGR) of 13.0%. This historical growth can be attributed to a rise in the occurrence of end stage renal disease, an aging demographic, enhanced availability to healthcare services, government-led initiatives and policies, coupled with increasing adoption of renal replacement therapies.

What's the Projected Size of the Global End Stage Renal Disease (ESRD) Drug Market by 2029?
In the coming years, the market size for drugs catering to end stage renal disease (esrd) is anticipated to experience swift expansion, reaching "$262.76 billion in 2029 at a compound annual growth rate (CAGR) of 15.3%. The expected growth throughout the forecast period can be associated with upcoming therapies and pharmaceutical innovations, escalated healthcare spending, the rising global impact of chronic kidney diseases, tailored medicine strategies, regulatory backing, and expedited approvals. During the forecast period, key trends such as increased occurrence of end stage renal disease, advancements in treatment methods, increased focus on precision medicine, advent of combination therapies, and technological integration into healthcare are expected to be seen.

View the full report here:
https://www.thebusinessresearchcompany.com/report/end-stage-renal-disease-esrd-drug-global-market-report

Top Growth Drivers in the End Stage Renal Disease (ESRD) Drug Industry: What's Accelerating the Market?
The growth of the end-stage renal disease (ESRD) drug market is anticipated to be accelerated by the increasing prevalence of obesity and diabetes. Obesity is characterized by an unusual or extreme accumulation of fat that presents a health risk, whereas diabetes is a long-term condition occurring when either the pancreas is insufficient in producing insulin, or the body fails to effectively use the insulin available. Managing fluid and electrolyte levels, blood pressure, and eliminating waste products through dialysis in people with kidney disease can enhance their overall health, possibly leading to weight loss and better blood sugar control. For example, World Obesity, a US-based association dedicated to obesity study and management, projected in March 2022 that the global count of obese individuals could potentially reach 892 million by 2025 and 1,025 million by 2030. Moreover, according to the National Health Service, a publicly subsidized healthcare system in the UK, in February 2023, they approximated that up to 5.5 million people, nearly 9% of the population, could be living with diabetes in the UK by 2030. Hence, the upsurge in obesity and diabetes cases is anticipated to propel the ESRD drug market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the End Stage Renal Disease (ESRD) Drug Market?
The trend of producing innovative products is a crucial factor in boosting the visibility in the market of end-stage renal disease (ESRD) drugs. The key players in the ESRD drug market are concentrating on designing novel solutions to maintain their market position. For instance, the UK-based pharmaceutical and biotech entity, GlaxoSmithKline PLC, announced in April 2022 that the US Food and Drug Administration (FDA) approved the New Drug Application (NDA) for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) potentially treating patients with chronic kidney disease anemia (CKD). The invention of this new product is rooted in the unique Nobel-prize-winning scientific discovery demonstrating how cells sense and adapt to the levels of oxygen present.

What Are the Main Segments in the End Stage Renal Disease (ESRD) Drug Market?
The end stage renal disease (esrd) drug market covered in this report is segmented -

1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products
2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:
1) By Calcimimetics: Cinacalcet, Etelcalcetide
2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol
3) By Sterols: Ergocalciferol, Cholecalciferol
4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate
5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate
6) By Other Products: Iron Supplements, Erythropoiesis-Stimulating Agents

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=9437&type=smp

Which Top Companies are Driving Growth in the End Stage Renal Disease (ESRD) Drug Market?
Major companies operating in the end stage renal disease (ESRD) drug market include Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA

Which Regions Will Dominate the End Stage Renal Disease (ESRD) Drug Market Through 2029?
North America was the largest region in the end stage renal disease (ESRD) drug market in 2024. The regions covered in the end stage renal disease (ESRD) drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9437

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.